Research programme: aggrecanase inhibitors - Rottapharm Biotech

Drug Profile

Research programme: aggrecanase inhibitors - Rottapharm Biotech

Alternative Names: CR 4144/CR 4152; CR 4153; CR 4167; CR 5259; CRB 0017

Latest Information Update: 24 Feb 2015

Price : $50

At a glance

  • Originator Rottapharm Madaus
  • Developer Rottapharm Biotech
  • Class Small molecules
  • Mechanism of Action ADAMTS5 protein inhibitors; Aggrecanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoarthritis

Most Recent Events

  • 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 01 Dec 2012 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top